Related Experiment Video
Updated: Feb 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review
Khodamorad Jamshidi1,2,3, Mohamad Gharehdaghi1,2,3, Sami Sam Hajialiloo1,2,3
1Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran.
Abstract:
Recent studies suggest that Denosumab reduces tumor size, therefore, makes the surgery easier with lower morbidity. However, some studies have reported several complications for this drug. So, this systematic review was performed to determine the effectiveness and safety of Denosumab in reducing bone destructions activity of giant cell tumor and skeletal-related events (SRE) in affected patients with giant cell tumor of bone (GCTB) and its recurrence. We explored studies in PubMed, and Cochrane Library. For this purpose, articles of various levels were retrieved until October 22, 2016. Two reviewers assessed the articles independently based on predefined criteria to extract the relevant data. Primary outcomes associated with skeletal-related event, overall survival, and secondary outcomes such as pain, quality of life and adverse events were evaluated and analyzed. The total population of this meta-analysis consisted of 686 patients. Of this population, 55% had primary GCTB and 45% had giant cell tumor recurrence, with 2% experiencing secondary recurrence. The results showed the effectiveness of Denosumab in reducing the tumor size due to inhibiting the Osteoclastogenesis. Denosumab didnot show any effect on reducing tumor recurrence, but, in cases where complete tumor surgery is not possible and tumor residuals may remain, Denosumab can be helpful. Also, the clinicians should consider the risk benefit of Denosumab.
Insights
Denosumab effectively reduces giant cell tumor of bone (GCTB) size, aiding surgery. However, it does not prevent tumor recurrence, and clinicians must weigh its benefits against potential risks.
Area of Science:
- Oncology
- Orthopedic Surgery
- Pharmacology
Background:
- Giant cell tumor of bone (GCTB) can cause significant bone destruction and skeletal-related events.
- Denosumab, an osteoclastogenesis inhibitor, has shown potential in reducing tumor size.
- Concerns exist regarding Denosumab's safety and efficacy in managing GCTB and its recurrence.
Purpose of the Study:
- To systematically review the effectiveness and safety of Denosumab for GCTB.
- To evaluate Denosumab's impact on reducing bone destruction and skeletal-related events (SREs).
- To assess Denosumab's role in primary GCTB and recurrent GCTB management.
Main Methods:
- Systematic review and meta-analysis of studies from PubMed and Cochrane Library up to October 2016.
- Independent data extraction and assessment by two reviewers.
- Evaluation of primary outcomes (SREs, overall survival) and secondary outcomes (pain, quality of life, adverse events).
Main Results:
- Denosumab demonstrated effectiveness in reducing GCTB size by inhibiting osteoclastogenesis.
- No significant effect of Denosumab was observed in reducing tumor recurrence rates.
- Denosumab may be beneficial in cases with unresectable tumors or residual disease post-surgery.
Conclusions:
- Denosumab is effective in decreasing GCTB size, potentially simplifying surgical interventions.
- Denosumab does not appear to reduce the recurrence of GCTB.
- Careful consideration of the risk-benefit profile is essential for clinicians when prescribing Denosumab for GCTB.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Systematic Sampling Method
Systematic sampling is one of the simplest methods...
Propagation of Uncertainty from Systematic Error
Systematic Error: Methodological and Sampling Errors
Sampling errors originate from improper sampling methods or the wrong sample population. These errors can be minimized by refining the sampling strategy. Defective instruments or faulty calibrations are the sources of instrumental...

